T

The Retina Group of Washington | Chevy Chase, MD

Research site

(Unclaimed)

Location

5454 Wisconsin Avenue Suite 650, Chevy Chase, Maryland, United States of America

Site insights

Top conditions

Top treatments

APL-2

bevacizumab

JNJ-81201887

Zimura

ranibizumab

Pegcetacoplan

zeaxanthin

Avacincaptad pegol

DHA

EPA

Parent organization

This site is a part of The Retina Group of Washington

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 11 total trials

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ...

Enrolling

Macular Degeneration

Geographic Atrophy

Other: Sham Procedure

Drug: JNJ-81201887

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Active, not recruiting

Geographic Atrophy

Drug: Triamcinolone

Other: Sham Procedure

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting

Geographic Atrophy Secondary to Age-related Macular Degeneration

Drug: PEGCETACOPLAN (APL-2)

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) w...

Active, not recruiting

Age-Related Macular Degeneration

Geographic Atrophy

Drug: avacincaptad pegol